State of Alaska Department of Revenue lifted its position in shares of Catalent Inc (NYSE:CTLT) by 63.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,957 shares of the company’s stock after purchasing an additional 10,034 shares during the quarter. State of Alaska Department of Revenue’s holdings in Catalent were worth $1,237,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CTLT. Principal Financial Group Inc. boosted its position in shares of Catalent by 1.4% during the first quarter. Principal Financial Group Inc. now owns 645,146 shares of the company’s stock valued at $26,186,000 after purchasing an additional 8,649 shares in the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Catalent by 29.3% during the first quarter. Westfield Capital Management Co. LP now owns 448,946 shares of the company’s stock valued at $18,223,000 after purchasing an additional 101,645 shares in the last quarter. GYL Financial Synergies LLC bought a new stake in shares of Catalent during the first quarter valued at approximately $217,000. Nordea Investment Management AB boosted its position in shares of Catalent by 1.3% during the first quarter. Nordea Investment Management AB now owns 109,340 shares of the company’s stock valued at $4,438,000 after purchasing an additional 1,350 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Catalent during the second quarter valued at approximately $413,000.
In other news, CEO John R. Chiminski sold 97,043 shares of the business’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $48.84, for a total value of $4,739,580.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gregory T. Lucier purchased 2,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was acquired at an average price of $51.64 per share, with a total value of $103,280.00. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.
Shares of NYSE:CTLT opened at $48.63 on Friday. The stock has a fifty day simple moving average of $50.82 and a two-hundred day simple moving average of $49.40. The stock has a market capitalization of $7.11 billion, a price-to-earnings ratio of 30.02, a PEG ratio of 2.34 and a beta of 1.70. Catalent Inc has a 12-month low of $29.23 and a 12-month high of $58.38. The company has a current ratio of 2.08, a quick ratio of 1.70 and a debt-to-equity ratio of 1.71.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, August 27th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.03. The business had revenue of $725.70 million during the quarter, compared to analysts’ expectations of $719.20 million. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. As a group, equities research analysts predict that Catalent Inc will post 1.82 EPS for the current year.
A number of brokerages have issued reports on CTLT. Robert W. Baird lifted their price objective on Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $53.00 price objective for the company in a research note on Tuesday, October 1st. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Morgan Stanley lifted their price objective on Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, August 28th. Finally, UBS Group lifted their price objective on Catalent to $64.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $56.29.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Cash Flow
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.